P. Ivy

B. Halmos, T. Mekhail, P. Ma, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416

J. Lewin, J. Jesberger, N. Ziats, 2005, Clinical Cancer Research.

Oxaliplatin: A Review of Evolving Concepts

S. Chaney, S. Mani, D. Bregman, 2002, Cancer investigation.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo

L. Collette, D. Lacombe, L. Seymour, 2014, European journal of cancer.

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer

P. LoRusso, J. Abrams, M. Simon, 2012, Breast Cancer Research and Treatment.

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

J. Doroshow, C. Takimoto, J. Grem, 2007, Clinical Cancer Research.

Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

P. Wen, D. Louis, R. Jain, 2008 .

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly

J. Doroshow, B. Conley, S. Kummar, 2007 .

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Thomas Benner, Percy Ivy, Marek Ancukiewicz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

P. Adamson, R. Murphy, F. Balis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboxypeptidase-G2 (CPDG2) and leucovorin (LV) rescue with and without addition of thymidine (Thd) for high-dose methotrexate (HDMTX) induced renal dysfunction

P. Adamson, F. Balis, B. Widemann, 2005 .

Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS.

H. Tawbi, E. Chu, J. Beumer, 2019, Journal of pharmaceutical and biomedical analysis.

A Phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow

P. Gaynon, M. Krailo, L. Ettinger, 1997, Cancer.

National Cancer Institute Formulary: A Public‐Private Partnership Providing Investigators Access to Investigational Anticancer Agents

B. Conley, P. Ivy, J. Zwiebel, 2017, Clinical pharmacology and therapeutics.

Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients

W. McCaskill-Stevens, B. Freidlin, J. Doroshow, 2020 .

A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer.

S. Mandrekar, M. Goetz, C. Erlichman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

G. Wilding, J. Kolesar, R. Brundage, 2011, Cancer Chemotherapy and Pharmacology.

Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.

R. Hermann, P. Adamson, F. Balis, 2004, Journal of the National Cancer Institute.

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer

R. Jain, A. Sorensen, T. Batchelor, 2009, Nature Reviews Clinical Oncology.

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

Jennie W. Taylor, R. Jain, A. Stemmer-Rachamimov, 2013, Neuro-oncology.

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

E. Winer, M. Birrer, Hang Lee, 2013, European journal of cancer.

Vessel Architectural Imaging Identifies Cancer Patient Responders to Anti-angiogenic Therapy

Bruce R. Rosen, Kim Mouridsen, Percy Ivy, 2013, Nature Medicine.

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

H. Mackay, E. Eisenhauer, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

Percy Ivy, A. Berkenblit, S. Cannistra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review of Cancer – Associated Fibroblasts and Therapiesthat Interfere with Their Activity

W. Timmer, N. Takebe, P. Harris, 2013 .

Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.

L. Rubinstein, P. LoRusso, S. Hunsberger, 2012, Journal of the National Cancer Institute.

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.

H. Mackay, A. Oza, H. Hirte, 2014, Gynecologic oncology.

A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors

M. Grever, T. Bekaii-Saab, E. Kraut, 2008, Clinical Cancer Research.

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial

K. Peck, L. Deangelis, P. Gutin, 2016, Clinical Cancer Research.

Phase I study (twice weekly schedule) of 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced refractory tumors

E. Zuhowski, M. Egorin, G. Chatta, 2005 .

A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: A Children's Oncology Group study

P. Adamson, Zhengjia Chen, M. Bernstein, 2008, Pediatric blood & cancer.

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

S. Baruchel, C. Ahern, P. Adamson, 2012, Cancer Chemotherapy and Pharmacology.

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate

R. Jeraj, M. Harrison, G. Wilding, 2011, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

S. Baruchel, C. Ahern, P. Adamson, 2011, Clinical Cancer Research.

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.

A. Tinker, H. Mackay, E. Eisenhauer, 2010, Gynecologic oncology.

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

Helen X. Chen, B. Rini, E. Borden, 2009, Clinical Cancer Research.

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

S. Spunt, L. McGregor, W. Furman, 2009, Cancer.

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

Erin L. Schenk, B. Costello, L. Doyle, 2021, Investigational New Drugs.

Expanding access to early phase trials: the CATCH-UP.2020 experience

M. Mooney, S. Gore, L. Rubinstein, 2022, JNCI cancer spectrum.

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

E. Vokes, D. Taber, T. Karrison, 2010, Investigational New Drugs.

A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function.

C. Takimoto, J. Kolesar, J. Wright, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

R. Neuwirth, K. Venkatakrishnan, C. Takimoto, 2010 .

Modernizing Eligibility Criteria for Molecularly Driven Trials.

Edward S. Kim, R. Schilsky, K. Hunt, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

A. Oza, S. Chia, M. Clemons, 2010, The oncologist.

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

U. Matulonis, B. Humphreys, R. Penson, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

J. Lewin, J. Duerk, J. Jesberger, 2007, Clinical Cancer Research.

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.

B. Lu, J. Albert, A. Sandler, 2006, Cancer research.

Models of Lung Cancer Inhibitor AZD 2171 and Fractionated Radiotherapy in Mouse Vascular Endothelial Growth Factor Tyrosine Kinase

B. Lu, J. Albert, A. Sandler, 2006 .

Randomized Phase II Designs

Larry Rubinstein, John Crowley, Percy Ivy, 2009, Clinical Cancer Research.

Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.

M. Mehta, T. Zhou, I. Pollack, 2008, Neuro-oncology.

A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer

S. Blank, H. Hochster, F. Muggia, 2013, International Journal of Gynecologic Cancer.

Spinal cord compression in widely metastatic Wilms' tumor. Paraplegia in two children with anaplastic wilms' tumor

R. Packer, G. Vezina, P. Ivy, 1992, Cancer.

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

F. Sarkar, S. Sheng, E. Heath, 2005, Clinical prostate cancer.

Improving the Quality of Abstract Reporting for Phase I Cancer Trials

G. Pond, L. Siu, A. Murgo, 2008, Clinical Cancer Research.

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Tracy T Batchelor, A Gregory Sorensen, Percy Ivy, 2012, Cancer research.

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

J. Kolesar, A. Razak, L. Siu, 2015, Investigational New Drugs.

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

C. Thng, B. Goh, E. Tan, 2011, Clinical Cancer Research.

LC–MS/MS assay for the quantitation of the ATR kinase inhibitor VX‐970 in human plasma

C. Bakkenist, E. Chu, A. Doyle, 2017, Journal of pharmaceutical and biomedical analysis.

A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer

F. Sarkar, S. Sheng, E. Heath, 2007 .

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

A. Iasonos, M. Gounder, D. Hyman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Tolerability, and Pharmacology of Bortezomib in Cancer Patients with Renal Failure Requiring Dialysis: Results from a Prospective Phase 1 Study.

C. Takimoto, S. Remick, M. Karol, 2007 .

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building

J. Lieberman, B. Pollock, S. Manuck, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers

A. Chak, C. Hoppel, P. Fu, 2009, Cancer Chemotherapy and Pharmacology.

Notch1 phenotype and clinical stage progression in non-small cell lung cancer

L. Rubinstein, J. Doroshow, Sherry X. Yang, 2015, Journal of Hematology & Oncology.

Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.

Mimi Y. Kim, M. Einstein, C. Runowicz, 2010, Gynecologic oncology.

Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Brachytherapy in Puerto Rico After Hurricane Maria

C. Kunos, P. Ivy, 2019, Front. Oncol..

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2009, Cancer Chemotherapy and Pharmacology.

LC–MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma

E. Chu, B. Kiesel, J. Beumer, 2017, Journal of pharmaceutical and biomedical analysis.

Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.

P. Ivy, M. Schoenfeldt, 2004, Oncology.

363 Dose of the molecularly targeted agents (MTA) in Phase 1 trials correlates with clinical benefit

L. Rubinstein, P. LoRusso, S. Hunsberger, 2010 .

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

S. Faria, Y. Oki, L. Medeiros, 2012, Leukemia & lymphoma.

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors

M. Cooney, A. Dowlati, S. Remick, 2011, Investigational New Drugs.

Phase I trial of intravenous 17-allylaminogeldanamycin (A) and oral sorafenib (B) in pretreated advanced malignancy: Plasma Hsp90α induction correlates with clinical benefit

E. Sausville, P. LoRusso, U. Vaishampayan, 2007 .

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors

M. Cooney, A. Dowlati, N. Meropol, 2012, Cancer Chemotherapy and Pharmacology.

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors.

E. Zuhowski, D. Trump, C. Belani, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

E. Sausville, P. LoRusso, M. Egorin, 2010, Clinical Cancer Research.

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

P. Wen, D. Louis, R. Jain, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer

P. LoRusso, U. Vaishampayan, M. Hussain, 2003, Investigational New Drugs.

A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer

S. Blank, H. Hochster, F. Muggia, 2013, International Journal of Gynecologic Cancer.

Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors

S. Spunt, L. McGregor, W. Furman, 2015, Journal of pediatric hematology/oncology.

Randomized Phase II Designs

M. LeBlanc, J. Crowley, D. Sargent, 2009, Clinical Cancer Research.

A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium.

A. Oza, S. Chia, M. Clemons, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.

Shing M. Lee, L. Minasian, Y. Cheung, 2016, Journal of Clinical Oncology.